|
Cephalon (Prior ChemGenex Pharmaceuticals) |
|
|
3715 Haven Avenue, Suite 100
Menlo Park, CA 94025 USA
phone:(650) 474-9800
fax:(650) 474-9808
|
|
| Symbol |
CXSPY, CSX |
| Exchange |
Pink, ASX |
| Founded |
0 |
| Employees |
|
|
|
| chemgenex.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Our mission at ChemGenex is to develop personalized medicines for the treatment of cancer. By focusing on validated targets in diseases with genetic components, we seek to bring targeted therapeutics to market that address chronic diseases with high unmet medical need. Our clinical pipeline of cancer drugs, coupled with our discovery and development programs, provide us with a solid foundation to meet these objectives. |
|
| Management |
| Greg Collier, Ph.D., Chief Executive Officer and Managing Director; Dennis Brown, Ph.D., President and Executive Director; James Campbell, Ph.D., M.B.A., Vice President of Operations; Rick Merrigan, M.B.A., Chief Financial Officer and Company Secretary; Ian Nisbet, Ph.D., Vice President of Oncology; Tina Herbert, M.B.A., Senior Director of Finance |
| |
|
|
|
|
|
|
|
| Keywords |
| Oncology, CML, personalized medicine, Leukemia, solid cancers, myelodysplastic syndrome, MDS |
|
|
|
| Description |
|
Our mission at ChemGenex is to develop personalized medicines for the treatment of cancer. By focusing on validated targets in diseases with genetic components, we seek to bring targeted therapeutics to market that address chronic diseases with high unmet medical need. Our clinical pipeline of cancer drugs, coupled with our discovery and development programs, provide us with a solid foundation to meet these objectives. |
|
| Products / Services |
Omapro (Omacetaxine mepesuccinate) is a first-in-class small molecule which as a single agent is being evaluated in clinical trials in a range of hematological malignancies. Omapro has a novel mode of action, and induces apoptosis by inhibition of protein synthesis, particularly Mcl-1. As Omapro acts independently of tyrosine kinase inhibitors, it may have therapeutic advantages for patients who have developed resistance to tyrosine kinase inhibitor therapy. Omapro is administered subcutaneously.
Quinamed� (amonafide dihydrochloride) is a synthetic organic compound with established anti-cancer clinical activity. We have recently discovered that amonafide affects a number of targets in the EGFR pathway. In NCI-sponsored clinical studies with amonafide monohydrochloride, response rates as high as 25% were observed in breast cancer. However, researchers also noted some unpredictable side effects. It was later discovered that differences in how patients metabolize the drug has a significant impact on toxicities. These metabolic differences can now be determined by testing a patient�s NAT2 genotype.
|
|
| Technology / Differentiation |
| Omapro has a novel mode of action, and induces apoptosis by inhibition of protein synthesis, particularly Mcl-1. As Omapro acts independently of tyrosine kinase inhibitors, it may have therapeutic advantages for patients who have developed resistance to tyrosine kinase inhibitor therapy |
|
|
| Strategy |
Our business strategy is to develop targeted therapeutics for the treatment of chronic diseases by exploiting our understanding of genetic variations associated with disease formation, drug response, or both. In doing so, we believe we will benefit patients and create value for stockholders.
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
